Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Sibp-A13 Formulation For
Cancer
Shanghai Institute Of Biological Products
P1
C
(36)
Sibp-A17
Cancer
Shanghai Institute Of Biological Products
P1
C
(36)
sim1811-03
Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
P1
C
(36)
Ski-G-801
Cancer
Oscotec Inc.
P1
C
(36)
snv1521
Cancer
Synnovation Therapeutics, Inc.
P1
C
(36)
sot201
Cancer
SOTIO Biotech AG
P1
C
(36)
sph7485
Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
P1
C
(36)
Sti-6129
Cancer
Sorrento Therapeutics, Inc.
P1
C
(36)
sw-682
Cancer
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
P1
C
(36)
sy-3505
Cancer
Shouyao Holdings (Beijing) Co. LTD
P1
C
(36)
sys6023
Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1
C
(36)
Sysa1801 For
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1
C
(36)
T-1201
Cancer
Taivex Therapeutics Corporation
P1
C
(36)
t-1301 capsules
Cancer
Taivex Therapeutics Corporation
P1
C
(36)
Tcr-Mage-A4 T-Cells
Cancer
Peking University
P1
C
(36)
Tcrt-Eso-A2
Cancer
Athenex, Inc.
P1
C
(36)
Tgrx-1942
Cancer
Shenzhen TargetRx Co., Ltd.
P1
C
(36)
Tolododekin Alfa
Cancer
Ankyra Therapeutics, Inc
P1
C
(36)
Torl-1-23
Cancer
TORL Biotherapeutics, LLC
P1
C
(36)
Torl-2-307-Adc
Cancer
TORL Biotherapeutics, LLC
P1
C
(36)
Torl-2-307-Mab
Cancer
TORL Biotherapeutics, LLC
P1
C
(36)
Torl-3-600
Cancer
TORL Biotherapeutics, LLC
P1
C
(36)
Torl-4-500
Cancer
TORL Biotherapeutics, LLC
P1
C
(36)
tqb3823 tablets
Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
P1
C
(36)
tr115
Cancer
Tarapeutics Science Inc.
P1
C
(36)
Showing 451 to 475 of 534 assets
Previous
Page 19 of 22
Next